Regimens of anti–PD-L/PD-L1 combined with antiangiogenic therapy have been efficient against a wide variety of solid tumors (Khan and Kerbel, 2018), such as endometrial cancer (Makker et al., 2020) and renal carcinoma (Taylor et al., 2020). Here, CD274 is linked to renal carcinoma.